The estimated Net Worth of Investments, Lpwong Roderic... is at least 323 百万$ dollars as of 11 May 2021. Investments Roderic owns over 725,000 units of Rocket Pharmaceuticals Inc stock worth over 294,206,065$ and over the last 6 years Investments sold RCKT stock worth over 29,021,750$.
Investments has made over 4 trades of the Rocket Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Investments sold 725,000 units of RCKT stock worth 29,021,750$ on 11 May 2021.
The largest trade Investments's ever made was selling 725,000 units of Rocket Pharmaceuticals Inc stock on 11 May 2021 worth over 29,021,750$. On average, Investments trades about 291,288 units every 126 days since 2018. As of 11 May 2021 Investments still owns at least 15,460,119 units of Rocket Pharmaceuticals Inc stock.
You can see the complete history of Investments Roderic stock trades at the bottom of the page.
Investments's mailing address filed with the SEC is 412 W 15th St FLOOR 9C/O, New York, NY 10011, USA.
Over the last 6 years, insiders at Rocket Pharmaceuticals Inc have traded over 45,364,690$ worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth 48,979,646$ . The most active insiders traders include Investments, Lpwong Roderic...、Mikael Dolsten、Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of 1,269,815$. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth 19,684$.
rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include: